200.54
+2.71%
Close of 9 Nov 2026, in INR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Kilitch Drugs (India)
Its shares trade on NSE under the ticker KILITCH.NS. It has been listed since 14 February 1994. In the fiscal year to 31 March 2026, it reported revenue of ₹2.35bn and net income of ₹301.7m. At that date it held total assets of ₹4.58bn and shareholders' equity of ₹2.80bn.
Kilitch Drugs (India) Ltd. engages in the manufacture and sale of pharmaceuticals, medicinal chemical, and botanical products. The company is headquartered in Mumbai, Maharashtra. The firm is primarily engaged in the development, manufacturing, and marketing of finished dosages. The Company’s products portfolio includes Parenteral and Nasal Products, Oral, Effervescent, Nutritional Products, Medical Devices, and Cosmetics and Herbal Products. Its Parenteral and Nasal Products has a range of products that help in gastroenterology, anti-inflammatory, anti-malaria, diagnostic, uterine stimulants, veterinary and many other areas in the form of ampoules and vials. The Company’s range of oral formulations includes tablets, capsules, dry syrups and oral powders. The Company’s medical devices offer a C-Seal brand. The company has a range of cosmetics ranging from oil, lotion and liquid to cream and paste in skin care, personal care, and hair care category. The firm has its manufacturing units located in India and Ethiopia.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 14 Feb 1994
- Employees
- 153
- Website
- kilitch.com ↗
Leadership
Pay as last reported
- Mr. Sunil JainChief Financial Officer₹1.5m
- Ms. Pushpa NyoupaneChief Compliance Officer, Company Secretary
- Mr. Mukund MehtaManaging Director, Executive Director₹6.0m
- Mrs. Mira MehtaManaging Director, since 2013₹2.4m
- Mr. Bhavin MehtaWholetime Director₹8.4m
- Mr. Dipen JainAdditional Non-Executive Independent Director
- Prof. Murti KrishnaNon-Executive Independent Director₹30,000
- Mr. Venkita RajanNon-Executive Independent Director₹4,440
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Kilitch Drugs manufactures Parenteral and Nasal Products for gastroenterology and anti-inflammatory treatments in India and Ethiopia.
- Kilitch Drugs offers a diverse portfolio including Oral, Effervescent, Nutritional Products, and Medical Devices like C-Seal.
- Kilitch Drugs has a presence in India and Ethiopia with manufacturing units for pharmaceuticals and botanical products.
Weaknesses
- Kilitch Drugs employs only 153 full-time employees across its operations in India and Ethiopia.
- Kilitch Drugs has a limited product range compared to larger pharmaceutical companies in the Health Care sector.
- Kilitch Drugs operates in a highly competitive market with no mention of global expansion strategies.
Opportunities
- Kilitch Drugs can expand its Parenteral and Nasal Products portfolio to include more anti-malaria and veterinary applications.
- Kilitch Drugs can leverage its manufacturing units in Ethiopia to enter new markets in Africa.
- Kilitch Drugs can grow its cosmetics and herbal products segment in the Indian market.
Threats
- Kilitch Drugs faces competition from larger pharmaceutical firms in the Health Care sector in India.
- Kilitch Drugs must navigate regulatory challenges in both India and Ethiopia for pharmaceutical manufacturing.
- Kilitch Drugs has a small workforce of 153 employees which may limit its ability to scale operations.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.